Pak Vladimir
Ther Deliv. 2014 Aug;5(8):885-92. doi: 10.4155/tde.14.59.
One approach to improving the activity of anticancer drugs is to bind them to the human α-fetoprotein (HAFP) that recognizes the tumor-associated cell-surface HAFP receptor. A drug can be bound to the HAFP by covalent conjugation or within a non-covalent complex. Specially designed linkers couple cytotoxins to the HAFP and ensure the stability of the HAFP-drug conjugate in the circulation and the activation of the drug in the cancer cell. On the other hand, AFP-drug non-covalent complexes can exploit the natural role of the AFP as a nutrition delivery "shuttle". In this article we review the design of HAFP-drug conjugates and AFP-drug complexes and their potential uses.
提高抗癌药物活性的一种方法是将它们与能识别肿瘤相关细胞表面甲胎蛋白（HAFP）受体的人甲胎蛋白（HAFP）结合。药物可以通过共价结合或在非共价复合物中与HAFP结合。经过特殊设计的连接子将细胞毒素与HAFP偶联，并确保HAFP-药物偶联物在循环中的稳定性以及药物在癌细胞中的激活。另一方面，AFP-药物非共价复合物可以利用AFP作为营养传递“穿梭载体”的天然作用。在本文中，我们综述了HAFP-药物偶联物和AFP-药物复合物的设计及其潜在用途。
